Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 326-339
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Figure 3 Portion of patients treated either with TMC435 at 75 mg/d or 150 mg/d or with placebo, combined with PEGylated interferon/ribavirin, who reached SVR24 (%) in the PILLAR study[15].
- Citation: Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World J Hepatol 2014; 6(5): 326-339
- URL: https://www.wjgnet.com/1948-5182/full/v6/i5/326.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i5.326